Aerin Medical Announces Results of Randomized Controlled Trial Supporting VivAer® for Treatment of Nasal Airway Obstruction With Nasal Valve Collapse

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians non-invasive solutions for the treatment of chronic nasal airway conditions, today announced that the International Forum of Allergy and Rhinology has published online three-month results from the VATRAC trial, confirming the safety and efficacy of VivAer® for the treatment of nasal airway obstruction (NAO) caused by nasal valve collapse (NVC).

In the study, those treated with VivAer showed significant improvement in nasal obstruction symptoms compared to the control group. This is the first randomized controlled trial of a non-invasive, radiofrequency treatment of NVC.

The VivAer procedure for Treatment of Nasal Airway Obstruction Study (VATRAC), a multi-center, prospective, single-blinded, randomized, sham-controlled trial, enrolled 117 patients who had extreme or severe NAO, based on the clinically validated Nasal Obstruction Symptom Evaluation (NOSE) Scale score, with NVC as a primary or significant contributor to their nasal obstruction symptoms. Patients were randomized to undergo in-office treatment with VivAer (treatment group) or an in-office sham procedure that replicated the treatment experience without delivering therapeutic radiofrequency energy (control group).

The VATRAC study met its primary and secondary endpoints, with treated patients demonstrating a significantly superior responder rate (88.3% of the treatment group patients had at least a 20% improvement in NOSE score versus 42.5% in the control group) and symptom reduction (55.1% improvement in mean NOSE score in the treatment group compared to 21.3% improvement in the control group). Statistically significant improvements were observed for treated patients in nasal congestion, nasal blockage, improved breathing and sleeping, and improved breathing during exercise or exertion. The authors noted that patients treated with VivAer experienced NAO symptom relief similar to those who underwent more invasive surgical procedures. Subgroup analysis of the data also showed that VivAer was equally effective in treating patients with static and dynamic (occurring during inhalation) NVC. Treatment with VivAer was generally well tolerated, with no serious adverse events related to the procedure.

NAO is a common condition that impacts more than 20 million Americans1 and can take a heavy toll on daily life. The most common symptoms include nasal congestion or stuffiness, trouble breathing through the nose, trouble sleeping, and difficulty breathing well during exercise or exertion. NVC contributes to nasal obstruction for 73% of highly symptomatic patients,2 but it is often under-diagnosed and left untreated. VivAer offers physicians a unique treatment modality that gently remodels tissue in the nasal valve, increasing its ability to resist collapse.

“We believe that one reason NVC is commonly overlooked is the scarcity of non-invasive treatment options as an alternative to surgical repair,” said Scott Wolf, M.D., founder and chief medical officer of Aerin Medical. “To date, more than 30,000 people have been treated with VivAer, and the strong VATRAC trial results reflect our commitment to building a robust body of clinical evidence to support the safety and effectiveness of this non-invasive device.”




Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.